217 filings
Page 2 of 11
8-K
uqa2mzy 8zi
10 Aug 23
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
4:18pm
S-8
57zfgc 0kycd
27 Jun 23
Registration of securities for employees
5:21pm
8-K
gbj717vk7n2zhlw2x4
27 Jun 23
Departure of Directors or Certain Officers
4:22pm
8-K
6jd0t4q bdrbfo4
27 Jun 23
Regulation FD Disclosure
9:00am
8-K
25x27j
22 May 23
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
5:46pm
8-K
d31oap
11 May 23
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
4:28pm
DEFA14A
3y4rvup
10 May 23
Additional proxy soliciting materials
6:33pm
8-K
1gah 4p6d
8 May 23
Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis
8:14am
8-K
abyn oblw
30 Mar 23
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
4:16pm
8-K
569rbym6uhs
28 Feb 23
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of
4:18pm
8-K
cnmbly2v4nd qsgpgu
15 Feb 23
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
4:17pm
8-K
t6v8gbi 21vsqc7u
30 Jan 23
Other Events
8:24am
424B3
9va e8sqv4mscp
23 Dec 22
Prospectus supplement
4:13pm
EFFECT
7jqt9vkrrdfxgcv
23 Dec 22
Notice of effectiveness
12:15am
CORRESP
f8k8mwv3
21 Dec 22
Correspondence with SEC
12:00am
UPLOAD
lvkyh4tno48451 rgv
20 Dec 22
Letter from SEC
12:00am